This presentation looks at the dynamic landscape of therapeutic antibody development, focusing on next-generation immuno-oncology therapeutics that target checkpoint inhibitors and incorporate the immune system’s defense strategies to modulate T-cell engagers. Through a comprehensive overview, attendees will gain insights into the history of antibody drugs, including key milestones and approved antibodies in immuno-oncology. The presentation will also highlight GenScript's technologies to advance therapeutic antibody development, offering innovative solutions tailored to each stage of the process. Discover how GenScript's expertise and state-of-the-art technologies can streamline workflow, optimize antibody leads, and facilitate the transition from preclinical studies to clinical trials.

Learning Objectives: 

1. Gain an understanding of the history and evolution of antibody drugs, including key milestones and therapeutic areas of focus.

2. Discuss GenScript's custom antibody generation and optimization services.

3. Review high-quality recombinant antibody and protein expression services.